

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Ashiya Mona</u> (Last) (First) (Middle) C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101 (Street) WATERTOWN MA 02472 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Disc Medicine, Inc. [IRON]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/10/2025	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/10/2025		S		68,766	D	\$54.29 ⁽¹⁾	539,845	I	See Footnotes ⁽⁶⁾⁽⁹⁾
Common Stock	03/10/2025		S		106,384	D	\$54.29 ⁽¹⁾	835,185	I	See Footnotes ⁽⁷⁾⁽⁹⁾
Common Stock	03/10/2025		S		26,596	D	\$54.29 ⁽¹⁾	208,795	I	See Footnotes ⁽⁸⁾⁽⁹⁾
Common Stock	03/10/2025		S		136	D	\$55.01 ⁽²⁾	539,709	I	See Footnotes ⁽⁶⁾⁽⁹⁾
Common Stock	03/10/2025		S		211	D	\$55.01 ⁽²⁾	834,974	I	See Footnotes ⁽⁷⁾⁽⁹⁾
Common Stock	03/10/2025		S		53	D	\$55.01 ⁽²⁾	208,742	I	See Footnotes ⁽⁸⁾⁽⁹⁾
Common Stock	03/11/2025		S		9,222	D	\$54.01 ⁽³⁾	530,487	I	See Footnotes ⁽⁶⁾⁽⁹⁾
Common Stock	03/11/2025		S		14,267	D	\$54.01 ⁽³⁾	820,707	I	See Footnotes ⁽⁷⁾⁽⁹⁾
Common Stock	03/11/2025		S		3,567	D	\$54.01 ⁽³⁾	205,175	I	See Footnotes ⁽⁸⁾⁽⁹⁾
Common Stock	03/12/2025		S		603	D	\$55.05 ⁽⁴⁾	529,884	I	See Footnotes ⁽⁶⁾⁽⁹⁾
Common Stock	03/12/2025		S		933	D	\$55.05 ⁽⁴⁾	819,774	I	See Footnotes ⁽⁷⁾⁽⁹⁾
Common Stock	03/12/2025		S		233	D	\$55.05 ⁽⁴⁾	204,942	I	See Footnotes ⁽⁸⁾⁽⁹⁾
Common Stock	03/12/2025		S		27,750	D	\$54.44 ⁽⁵⁾	502,134	I	See Footnotes ⁽⁶⁾⁽⁹⁾
Common Stock	03/12/2025		S		42,930	D	\$54.44 ⁽⁵⁾	776,844	I	See Footnotes ⁽⁷⁾⁽⁹⁾
Common Stock	03/12/2025		S		10,733	D	\$54.44 ⁽⁵⁾	194,209	I	See Footnotes ⁽⁸⁾⁽⁹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Deemed Execution Date, if any (e.g., puts, calls, warrants, options, convertible securities) (Month/Day/Year)	5. Transaction Code (Instr. 8)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Underlying Security (Instr. 4 and 5)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Underlying Security (Instr. 4 and 5)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	Date Exercisable	Expiration Date	Title	Number of Shares		

Explanation of Responses:

1. Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of \$54.00 to a high of \$54.66 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
2. Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of \$55.01 to a high of \$55.02 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
3. Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of \$54.00 to a high of \$54.07 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
4. Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of \$55.03 to a high of \$55.11 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
5. Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of \$54.00 to a high of \$54.96 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
6. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
7. These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
8. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
9. Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

/s/ Mona Ashiya 03/12/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.